Lataa...
Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer
SIMPLE SUMMARY: About one third of all breast cancers are classified as HER2-positive due to high levels of the HER2 cell surface protein. Drugs that target HER2 have been mostly successful, but this type of cancer returns at a high frequency once treatment has been completed. The high levels of HER...
Tallennettuna:
| Julkaisussa: | Cancers (Basel) |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8230691/ https://ncbi.nlm.nih.gov/pubmed/34208071 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13122922 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|